Profound inhibition of antigen-specific T-cell effector functions by dasatinib

Clinical Cancer Research

Volumn 14, Issue 8, 2008, Pages 2484-2491

  Weichsel, Ralf ^a   Dix, Carolin ^a   Wooldridge, Linda ^b   Clement, Matthew ^b   Fenton May, Angharad ^b   Sewell, Andrew K ^b   Zezula, Josef ^c   Greiner, Elisabeth ^c   Gostick, Emma ^d   Price, David A ^d   Einsele, Hermann ^a   Seggewiss, Ruth ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DASATINIB; PROTEIN TYROSINE KINASE INHIBITOR; STAUROSPORINE;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 42249088418     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4393     Document Type: Article

References (37)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
2. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;346:683-93.
3. Bornhauser M, Kroger N, Schwerdtfeger R, et al. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicenter study. Eur J Haematol 2006;76:9-17.
4. Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002;100:1590-5.
5. Olavarria E, Craddock C, Dazzi F, et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002;99:3861-2.
6. + T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. Cancer Immunol Immunother 2007;56:849-61.
7. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004;104:1094-9.
8. Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004;18:1332-9.
9. Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005;105:2473-9.
10. Zamoyska R, Basson A, Filby A, Legname G, Lovatt M, Seddon B. The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunol Rev 2003;191:107-18.
11. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
12. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:3207-13.
13. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143-50.
14. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6- methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61.
15. Das J, Chen P, Norris D, et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[(6-(4-(2-hydroxyethyl)-1-piperazinyl)- 2-methyl-4-pyrimidinyl)amino]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 2006;49:6819-32.
16. Dechanet J, Merville P, Lim A, et al. Implication of γδ T cells in the human immune response to cytomegalovirus. J Clin Invest 1999;103:1437-49.
17. + γδ T cells play protective roles at an early phase of murine cytomegalovirus infection through production of interferon-γ. Immunology 2000;99:187-94.
18. Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor h receptor fusion oncogene. Blood 2002;100:1088-91.
19. Betts MR, Casazza JP, Patterson BA, et al. Putative immunodominant human immunodeficiency virusspecific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J Virol 2000;74:9144-51.
20. Hutchinson SL, Wooldridge L, Tafuro S, et al. The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. J Biol Chem 2003;278:24285-93.
21. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
22. Wooldridge L, Hutchinson SL, Choi EM, et al. Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface. J Immunol 2003;171:6650-60.
23. Green AE, Lissina A, Hutchinson SL, et al. Recognition of nonpeptide antigens by human Vγ9Vδ2 T cells requires contact with cells of human origin. Clin Exp Immunol 2004;136:472-82.
24. Dasatinib (BMS-354825), Oncologic drug advisory committee (ODAC) briefing document, NDA 21-986: Bristol-Myers-Squibb Company; 2006 Jun 2. Available from: http://www.fda.gov/ohrms/dockets/AC/06/briefing/2006-4220-B1- 01BristolMyersSquibb-Background.pdf.
25. + effector and memory T cell generation. Nat Immunol 2003;4:835-42.
26. Mumprecht S, Matter M, Pavelic V, Ochsenbein AF. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 2006;108:3406-13.
27. Sinai P, Berg RE, Haynie JM, Egorin MJ, Ilaria RL, Jr., Forman J. Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo. J Immunol 2007;178:2028-37.
28. Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 1995;375:148-51.
29. Slifka MK, Whitton JL. Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat Immunol 2001;2:711-7.
30. + T cell responses. Proc Natl Acad Sci U S A 2006;103:16388-93.
31. Leder C, Ortler S, Seggewiss R, Einsele H, Wiendl H. Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol 2007;35:1266-71.
32. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002;2:735-47.
33. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005;139:101-11.
34. Hayday A, Geng L. γ δ cells regulate autoimmunity. Curr Opin Immunol 1997;9:884-9.
35. Borsellino G, Koul O, Placido R, et al. Evidence for a role of γδ T cells in demyelinating diseases as determined by activation states and responses to lipid antigens. J Neuroimmunol 2000;107:124-9.
36. Yu XZ, Levin SD, Madrenas J, Anasetti C. Lck is required for activation-induced T cell death after TCR ligation with partial agonists. J Immunol 2004;172:1437-43.
37. Chuah C, Lim TH, Lim AS, et al. Dasatinib induces a response in malignant thymoma. J Clin Oncol 2006;24:e56-8.